This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.Need a new registration confirmation email? Click here

AGN, LLY, BIIB, CELG And AMGN, Pushing Health Care Sector Downward

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

Two out of the three major indices are trading up today with the
Dow Jones Industrial Average (
^DJI) trading up 1 points (0.0%) at 15,277 as of Thursday, May 16, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 1,398 issues advancing vs. 1,509 declining with 138 unchanged.

TheStreet Ratings group would like to highlight 5 stocks pushing the sector lower today:

5.
Allergan (
AGN) is one of the companies pushing the Health Care sector lower today. As of noon trading, Allergan is down $1.78 (-1.7%) to $101.04 on average volume Thus far, 1.2 million shares of Allergan exchanged hands as compared to its average daily volume of 1.7 million shares. The stock has ranged in price between $100.09-$102.50 after having opened the day at $102.50 as compared to the previous trading day's close of $102.82.

Allergan, Inc. operates as a multi-specialty healthcare company primarily in the United States, Europe, Latin America, and the Asia Pacific. Allergan has a market cap of $30.8 billion and is part of the drugs industry. The company has a P/E ratio of 27.8, above the S&P 500 P/E ratio of 17.7. Shares are up 12.1% year to date as of the close of trading on Wednesday.

TheStreet Ratings rates Allergan as a
buy. The company's strengths can be seen in multiple areas, such as its revenue growth, impressive record of earnings per share growth, notable return on equity, expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full
Allergan Ratings Report now.